Stabilization of Protein-Protein Interactions in chemical biology and drug discovery

Progress in Biophysics and Molecular Biology

Volumn 119, Issue 1, 2015, Pages 10-19

  Bier, David ^a,b   Thiel, Philipp ^c   Briels, Jeroen ^a,b   Ottmann, Christian ^a,b  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Interface stabilization; Natural products; Protein ligand interaction; Small molecules; X ray crystallography

Indexed keywords

BIOLOGICAL PRODUCT; PROTEIN;

CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; METABOLISM; PROCEDURES; PROTEIN PROTEIN INTERACTION;

BIOLOGICAL PRODUCTS; DRUG DISCOVERY; HUMANS; PROTEIN INTERACTION MAPS; PROTEINS;

EID: 84940891771     PISSN: 00796107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbiomolbio.2015.05.002     Document Type: Review

References (93)

1. Anders C., Higuchi Y., Koschinsky K., Bartel M., Schumacher B., Thiel P., Nitta H., Preisig-Müller R., Schlichthörl G., Renigunta V., Ohkanda J., Daut J., Kato N., Ottmann C. A semisynthetic fusicoccane stabilizes a protein-protein interaction and enhances the expression of K+ channels at the cell surface. Chem. Biol. 2013, 20:583-593. 10.1016/j.chembiol.2013.03.015.
2. Armstrong N., Gouaux E. Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core. Neuron 2000, 28:165-181. 10.1016/S0896-6273(00)00094-5.
3. Ballio A., Chain E.B., De Leo P., Erlanger B.F., Mauri M., Tonolo A. Fusicoccin: a new wilting toxin produced by Fusicoccum amygdali del. Nature 1964, 203:297. 10.1038/203297a0.
4. Barker C.J., Wright J., Hughes P.J., Kirk C.J., Michell R.H. Complex changes in cellular inositol phosphate complement accompany transit through the cell cycle. Biochem. J. 2004, 380:465-473. 10.1042/BJ20031872.
5. Bierer B.E., Mattila P.S., Standaert R.F., Herzenberg L.a., Burakoff S.J., Crabtree G., Schreiber S.L. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:9231-9235. 10.1073/pnas.87.23.9231.
6. Bresnick A.R., Weber D.J., Zimmer D.B. S100 proteins in cancer. Nat. Rev. Cancer 2015, 15:96-109. 10.1038/nrc3893.
7. Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., Schreiber S.L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994, 369:756-758. 10.1038/369756a0.
8. Bulawa C.E., Connelly S., DeVit M., Wang L., Weigel C., Fleming J.a., Packman J., Powers E.T., Wiseman R.L., Foss T.R., Wilson I.a., Kelly J.W., Labaudiniere R. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc. Natl. Acad. Sci. 2012, 109:9629-9634. 10.1073/pnas.1121005109.
9. Choi J., Chen J., Schreiber S.L., Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 1996, 273:239-242.
10. Chung H.J., Sehnke P.C., Ferl R.J. The 14-3-3 proteins: cellular regulators of plant metabolism. Trends Plant Sci. 1999, 4:367-371. 10.1016/S1360-1385(99)01462-4.
11. Classen S., Olland S., Berger J.M. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10629-10634. 10.1073/pnas.1832879100.
12. Cormier A., Marchand M., Ravelli R.B.G., Knossow M., Gigant B. Structural insight into the inhibition of tubulin by vinca domain peptide ligands. EMBO Rep. 2008, 9:1101-1106. 10.1038/embor.2008.171.
13. De Vries-van Leeuwen I.J., da Costa Pereira D., Flach K.D., Piersma S.R., Haase C., Bier D., Yalcin Z., Michalides R., Feenstra K.A., Jiménez C.R., de Greef T.F.A., Brunsveld L., Ottmann C., Zwart W., de Boer A.H. Interaction of 14-3-3 proteins with the estrogen receptor alpha F domain provides a drug target interface. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:8894-8899. 10.1073/pnas.1220809110.
14. Dharmasiri N., Dharmasiri S., Estelle M. The F-box protein TIR1 is an auxin receptor. Nature 2005, 435:441-445. 10.1038/nature03543.
15. Dumaz N., Marais R. Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. J. Biol. Chem. 2003, 278:29819-29823. 10.1074/jbc.C300182200.
16. Falkenberg K.J., Johnstone R.W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 2014, 13:673-691. 10.1038/nrd4360.
17. Garrett S.C., Hodgson L., Rybin A., Toutchkine A., Hahn K.M., Lawrence D.S., Bresnick A.R. A biosensor of S100A4 metastasis factor activation: inhibitor screening and cellular activation dynamics. Biochemistry 2008, 47:986-996. 10.1021/bi7021624.
18. Germain P., Gaudon C., Pogenberg V., Sanglier S., Van Dorsselaer A., Royer C.a., Lazar M.a., Bourguet W., Gronemeyer H. Differential action on coregulator interaction defines inverse retinoid agonists and neutral antagonists. Chem. Biol. 2009, 16:479-489. 10.1016/j.chembiol.2009.03.008.
19. Gerritz S.W., Cianci C., Kim S., Pearce B.C., Deminie C., Discotto L., McAuliffe B., Minassian B.F., Shi S., Zhu S., Zhai W., Pendri A., Li G., Poss M.A., Edavettal S., McDonnell P.A., Lewis H.A., Maskos K., Mörtl M., Kiefersauer R., Steinbacher S., Baldwin E.T., Metzler W., Bryson J., Healy M.D., Philip T., Zoeckler M., Schartman R., Sinz M., Leyva-Grado V.H., Hoffmann H.-H., Langley D.R., Meanwell N.A., Krystal M. Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:15366-15371. 10.1073/pnas.1107906108.
20. Goley E.D., Welch M.D. The ARP2/3 complex: an actin nucleator comes of age. Nat. Rev. Mol. Cell. Biol. 2006, 7:713-726. 10.1038/nrm2026.
21. Gotti B., Duverger D., Bertin J., Carter C., Dupont R., Frost J., Gaudilliere B., MacKenzie E.T., Rousseau J., Scatton B. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I. Evidence for efficacy in models of focal cerebral ischemia. J. Pharmacol. Exp. Ther. 1988, 247:1211-1221.
22. Graves B., Thompson T., Xia M., Janson C., Lukacs C., Deo D., Di Lello P., Fry D., Garvie C., Huang K.-S., Gao L., Tovar C., Lovey A., Wanner J., Vassilev L.T. Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:11788-11793. 10.1073/pnas.1203789109.
23. Griffith J.P., Kim J.L., Kim E.E., Sintchak M.D., Thomson J.A., Fitzgibbon M.J., Fleming M.A., Caron P.R., Hsiao K., Navia M.A. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell 1995, 82:507-522.
24. Handschumacher R.E., Harding M.W., Rice J., Drugge R.J., Speicher D.W. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 1984, 226:544-547. (80-.).
25. Honigberg L.A., Smith A.M., Sirisawad M., Verner E., Loury D., Chang B., Li S., Pan Z., Thamm D.H., Miller R.A., Buggy J.J. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:13075-13080. 10.1073/pnas.1004594107.
26. Honma Y., Ishii Y., Sassa T., Asahi K.I. Treatment of human promyelocytic leukemia in the SCID mouse model with cotylenin A, an inducer of myelomonocytic differentiation of leukemia cells. Leuk. Res. 2003, 27:1019-1025. 10.1016/S0145-2126(03)00071-7.
27. Honma Y., Kasukabe T., Yamori T., Kato N., Sassa T. Antitumor effect of cotylenin A plus interferon-??: possible therapeutic agents against ovary carcinoma. Gynecol. Oncol. 2005, 99:680-688. 10.1016/j.ygyno.2005.07.015.
28. Huai Q., Kim H.-Y., Liu Y., Zhao Y., Mondragon A., Liu J.O., Ke H. Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:12037-12042. 10.1073/pnas.192206699.
29. Jin R., Clark S., Weeks A.M., Dudman J.T., Gouaux E., Partin K.M. Mechanism of positive allosteric modulators acting on AMPA receptors. J. Neurosci. 2005, 25:9027-9036. 10.1523/JNEUROSCI.2567-05.2005.
30. Kaae B.H., Harpsøe K., Kastrup J.S., Sanz A.C., Pickering D.S., Metzler B., Clausen R.P., Gajhede M., Sauerberg P., Liljefors T., Madsen U. Structural proof of a dimeric positive modulator bridging two identical AMPA receptor-binding sites. Chem. Biol. 2007, 14:1294-1303. 10.1016/j.chembiol.2007.10.012.
31. Karakas E., Simorowski N., Furukawa H. Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors. Nature 2011, 475:249-253. 10.1038/nature10180.
32. Kasukabe T., Okabe-Kado J., Kato N., Sassa T., Honma Y. Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res. 2005, 7:R1097-R1110. 10.1186/bcr1344.
33. Katsir L., Schilmiller A.L., Staswick P.E., He S.Y., Howe G.A. COI1 is a critical component of a receptor for jasmonate and the bacterial virulence factor coronatine. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:7100-7105. 10.1073/pnas.0802332105.
34. Khoo K.H., Hoe K.K., Verma C.S., Lane D.P. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat. Rev. Drug Discov. 2014, 13:217-236. 10.1038/nrd4236.
35. Kim T.-W., Wang Z.-Y. Brassinosteroid signal transduction from receptor kinases to transcription factors. Annu. Rev. Plant Biol. 2010, 61:681-704. 10.1146/annurev.arplant.043008.092057.
36. Le Maire A., Teyssier C., Erb C., Grimaldi M., Alvarez S., de Lera A.R., Balaguer P., Gronemeyer H., Royer C.A., Germain P., Bourguet W. A unique secondary-structure switch controls constitutive gene repression by retinoic acid receptor. Nat. Struct. Mol. Biol. 2010, 17:801-807. 10.1038/nsmb.1855.
37. Li Y., Koiso Y., Kobayashi H., Hashimoto Y., Iwasaki S. Ustiloxins, new antimitotic cyclic peptides: interaction with porcine brain tubulin. Biochem. Pharmacol. 1995, 49:1367-1372. 10.1016/0006-2952(95)00072-8.
38. Liu J., Farmer J.D., Lane W.S., Friedman J., Weissman I., Schreiber S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991, 66:807-815. 10.1016/0092-8674(91)90124-H.
39. Liu Y., Sheng J., Fokine A., Meng G., Shin W.-H., Long F., Kuhn R.J., Kihara D., Rossmann M.G. Virus structure. Structure and inhibition of EV-D68, a virus that causes respiratory illness in children. Science 2015, 347:71-74. 10.1126/science.1261962.
40. Lorenzo O., Chico J.M., Sánchez-Serrano J.J., Solano R. JASMONATE-INSENSITIVE1 encodes a MYC transcription factor essential to discriminate between different jasmonate-regulated defense responses in Arabidopsis. Plant Cell. 2004, 16:1938-1950. 10.1105/tpc.022319.
41. Madauss K.P., Grygielko E.T., Deng S.-J., Sulpizio A.C., Stanley T.B., Wu C., Short S.a., Thompson S.K., Stewart E.L., Laping N.J., Williams S.P., Bray J.D. A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol. Endocrinol. 2007, 21:1066-1081. 10.1210/me.2006-0524.
42. Malashkevich V.N., Dulyaninova N.G., Ramagopal U.a., Liriano M.a., Varney K.M., Knight D., Brenowitz M., Weber D.J., Almo S.C., Bresnick A.R. Phenothiazines inhibit S100A4 function by inducing protein oligomerization. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:8605-8610. 10.1073/pnas.0913660107.
43. Melcher K., Ng L.-M., Zhou X.E., Soon F.-F., Xu Y., Suino-Powell K.M., Park S.-Y., Weiner J.J., Fujii H., Chinnusamy V., Kovach A., Li J., Wang Y., Li J., Peterson F.C., Jensen D.R., Yong E.-L., Volkman B.F., Cutler S.R., Zhu J.-K., Xu H.E. A gate-latch-lock mechanism for hormone signalling by abscisic acid receptors. Nature 2009, 462:602-608. 10.1038/nature08613.
44. Millard C.J., Watson P.J., Celardo I., Gordiyenko Y., Cowley S.M., Robinson C.V., Fairall L., Schwabe J.W.R. Class I HDACs share a common mechanism of regulation by inositol phosphates. Mol. Cell. 2013, 51:57-67. 10.1016/j.molcel.2013.05.020.
45. Molzan M., Kasper S., Röglin L., Skwarczynska M., Sassa T., Inoue T., Breitenbuecher F., Ohkanda J., Kato N., Schuler M., Ottmann C. Stabilization of physical RAF/14-3-3 interaction by cotylenin A as treatment strategy for RAS mutant cancers. ACS Chem. Biol. 2013, 8:1869-1875. 10.1021/cb4003464.
46. Molzan M., Ottmann C. Synergistic binding of the phosphorylated S233- and S259-binding sites of C-RAF to one 14-3-3ζ dimer. J. Mol. Biol. 2012, 423:486-495. 10.1016/j.jmb.2012.08.009.
47. Molzan M., Schumacher B., Ottmann C.C., Baljuls A., Polzien L., Weyand M., Thiel P., Rose R., Rose M., Kuhenne P., Kaiser M., Rapp U.R., Kuhlmann J. Impaired binding of 14-3-3 to C-RAF in Noonan syndrome suggests new approaches in diseases with increased Ras signaling. Mol. Cell. Biol. 2010, 30:4698-4711. 10.1128/MCB.01636-09.
48. Monaco H.L., Rizzi M., Coda A. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science 1995, 268:1039-1041.
49. Ng B., Connors L.H., Davidoff R., Skinner M., Falk R.H. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch. Intern. Med. 2005, 165:1425-1429. 10.1001/archinte.165.12.1425.
50. Nolen B.J., Tomasevic N., Russell A., Pierce D.W., Jia Z., McCormick C.D., Hartman J., Sakowicz R., Pollard T.D. Characterization of two classes of small molecule inhibitors of Arp2/3 complex. Nature 2009, 460:1031-1034. 10.1038/nature08231.
51. Noton S.L., Simpson-Holley M., Medcalf E., Wise H.M., Hutchinson E.C., McCauley J.W., Digard P. Studies of an influenza A virus temperature-sensitive mutant identify a late role for NP in the formation of infectious virions. J. Virol. 2009, 83:562-571. 10.1128/JVI.01424-08.
52. Ottmann C., Marco S., Jaspert N., Marcon C., Schauer N., Weyand M., Vandermeeren C., Duby G., Boutry M., Wittinghofer A., Rigaud J.-L., Oecking C. Structure of a 14-3-3 coordinated hexamer of the plant plasma membrane H+ -ATPase by combining X-ray crystallography and electron cryomicroscopy. Mol. Cell. 2007, 25:427-440. 10.1016/j.molcel.2006.12.017.
53. Ottmann C., Weyand M., Sassa T., Inoue T., Kato N., Wittinghofer A., Oecking C. A structural rationale for selective stabilization of anti-tumor interactions of 14-3-3 proteins by cotylenin A. J. Mol. Biol. 2009, 386:913-919.
54. Patton J.T., Mayo L.D., Singhi A.D., Gudkov A.V., Stark G.R., Jackson M.W. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res. 2006, 66:3169-3176. 10.1158/0008-5472.CAN-05-3832.
55. Peyroche A., Antonny B., Robineau S., Acker J., Cherfils J., Jackson C.L. Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein complex: involvement of specific residues of the Sec7 domain. Mol. Cell. 1999, 3:275-285.
56. Ranaivoson F.M., Gigant B., Berritt S., Joullié M., Knossow M. Structural plasticity of tubulin assembly probed by vinca-domain ligands. Acta Crystallogr. D. Biol. Crystallogr. 2012, 68:927-934. 10.1107/S0907444912017143.
57. Ravelli R.B.G., Gigant B., Curmi P.A., Jourdain I., Lachkar S., Sobel A., Knossow M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004, 428:198-202. 10.1038/nature02393.
58. Ren J., Wu L., Xin W.Q., Chen X., Hu K. Synthesis and biological evaluation of novel 4β-(1,3,4-oxadiazole-2-amino)-podophyllotoxin derivatives. Bioorg. Med. Chem. Lett. 2012, 22:4778-4782. 10.1016/j.bmcl.2012.05.059.
59. Renault L., Guibert B., Cherfils J. Structural snapshots of the mechanism and inhibition of a guanine nucleotide exchange factor. Nature 2003, 426:525-530. 10.1038/nature02197.
60. Richon V.M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R.A., Marks P.A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:3003-3007.
61. Roca J., Ishida R., Berger J.M., Andoh T., Wang J.C. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:1781-1785.
62. Rose R., Erdmann S., Bovens S., Wolf A., Rose M., Hennig S., Waldmann H., Ottmann C. Identification and structure of small-molecule stabilizers of 14-3-3 protein-protein interactions. Angew. Chem. Int. Ed. Engl. 2010, 49:4129-4132. 10.1002/anie.200907203.
63. Rossmann M.G. Viral cell recognition and entry. Protein Sci. 1994, 3:1712-1725. 10.1002/pro.5560031010.
64. Santiago J., Henzler C., Hothorn M. Molecular mechanism for plant steroid receptor activation by somatic embryogenesis co-receptor kinases. Science 2013, 341:889-892. 10.1126/science.1242468.
65. Seamon K.B., Padgett W., Daly J.W. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:3363-3367.
66. Sheard L.B., Tan X., Mao H., Withers J., Ben-Nissan G., Hinds T.R., Kobayashi Y., Hsu F.-F., Sharon M., Browse J., He S.Y., Rizo J., Howe G.A., Zheng N. Jasmonate perception by inositol-phosphate-potentiated COI1-JAZ co-receptor. Nature 2010, 468:400-405. 10.1038/nature09430.
67. Shearwin K.E., Timasheff S.N. Effect of colchicine analogues on the dissociation of alpha beta tubulin into subunits: the locus of colchicine binding. Biochemistry 1994, 33:894-901.
68. Shimada A., Ueguchi-Tanaka M., Nakatsu T., Nakajima M., Naoe Y., Ohmiya H., Kato H., Matsuoka M. Structural basis for gibberellin recognition by its receptor GID1. Nature 2008, 456:520-523. 10.1038/nature07546.
69. Skwarczynska M., Molzan M., Ottmann C. Activation of NF-κB signalling by fusicoccin-induced dimerization. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E377-E386. 10.1073/pnas.1212990110.
70. Smith T.J., Kremer M.J., Luo M., Vriend G., Arnold E., Kamer G., Rossmann M.G., McKinlay M.a., Diana G.D., Otto M.J. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science 1986, 233:1286-1293. 10.1126/science.3018924.
71. Sun Y., Olson R., Horning M., Armstrong N., Mayer M., Gouaux E. Mechanism of glutamate receptor desensitization. Nature 2002, 417:245-253. 10.1038/417245a.
72. Sunahara R.K., Dessauer C.W., Whisnant R.E., Kleuss C., Gilman A.G. Interaction of Gsalpha with the cytosolic domains of mammalian adenylyl cyclase. J. Biol. Chem. 1997, 272:22265-22271.
73. Svennelid F., Olsson A., Piotrowski M., Rosenquist M., Ottman C., Larsson C., Oecking C., Sommarin M. Phosphorylation of Thr-948 at the C terminus of the plasma membrane H(+)-ATPase creates a binding site for the regulatory 14-3-3 protein. Plant Cell. 1999, 11:2379-2391. 10.1105/tpc.11.12.2379.
74. Tan X., Calderon-Villalobos L.I.A., Sharon M., Zheng C., Robinson C.V., Estelle M., Zheng N. Mechanism of auxin perception by the TIR1 ubiquitin ligase. Nature 2007, 446:640-645. 10.1038/nature05731.
75. Tesmer J.J. Crystal structure of the catalytic domains of adenylyl cyclase in a complex with GsaGTPgS. Science 1997, 278:1907-1916. (80-.). 10.1126/science.278.5345.1907.
76. Thiel P., Kaiser M., Ottmann C. Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery?. Angew. Chem. Int. Ed. 2012, 51:2012-2018. 10.1002/anie.201107616.
77. Tovar C., Rosinski J., Filipovic Z., Higgins B., Kolinsky K., Hilton H., Zhao X., Vu B.T., Qing W., Packman K., Myklebost O., Heimbrook D.C., Vassilev L.T. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1888-1893. 10.1073/pnas.0507493103.
78. Tse C., Shoemaker A.R., Adickes J., Anderson M.G., Chen J., Jin S., Johnson E.F., Marsh K.C., Mitten M.J., Nimmer P., Roberts L., Tahir S.K., Xiao Y., Yang X., Zhang H., Fesik S., Rosenberg S.H., Elmore S.W. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008, 68:3421-3428. 10.1158/0008-5472.CAN-07-5836.
79. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., Liu E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848. 10.1126/science.1092472.
80. Verdin E., Ott M. 50 Years of protein acetylation: from gene regulation to Epigenetics, metabolism and beyond. Nat. Rev. Mol. Cell. Biol. 2014, 16:258-264. 10.1038/nrm3931.
81. Wang C., Cormier A., Gigant B., Knossow M. Insight into the GTPase activity of tubulin from complexes with stathmin-like domains. Biochemistry 2007, 46:10595-10602. 10.1021/bi701147f.
82. Wang L., Zuercher W.J., Consler T.G., Lambert M.H., Miller A.B., Orband-Miller L.a., McKee D.D., Willson T.M., Nolte R.T. X-ray crystal structures of the estrogen-related receptor-gamma ligand binding domain in three functional states reveal the molecular basis of small molecule regulation. J. Biol. Chem. 2006, 281:37773-37781. 10.1074/jbc.M608410200.
83. Wang X., Kota U., He K., Blackburn K., Li J., Goshe M.B., Huber S.C., Clouse S.D. Sequential transphosphorylation of the BRI1/BAK1 receptor kinase complex impacts early events in brassinosteroid signaling. Dev. Cell. 2008, 15:220-235. 10.1016/j.devcel.2008.06.011.
84. Wang Z.Y., Seto H., Fujioka S., Yoshida S., Chory J. BRI1 is a critical component of a plasma-membrane receptor for plant steroids. Nature 2001, 410:380-383. 10.1038/35066597.
85. Watson P.J., Fairall L., Santos G.M., Schwabe J.W.R. Structure of HDAC3 bound to co-repressor and inositol tetraphosphate. Nature 2012, 481:335-340. 10.1038/nature10728.
86. Wen Y.-D., Perissi V., Staszewski L.M., Yang W.-M., Krones A., Glass C.K., Rosenfeld M.G., Seto E. The histone deacetylase-3 complex contains nuclear receptor corepressors. Proc. Natl. Acad. Sci. 2000, 97:7202-7207. 10.1073/pnas.97.13.7202.
87. West A.C., Johnstone R.W. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest 2014, 124:30-39. 10.1172/JCI69738.30.
88. Würtele M., Jelich-Ottmann C., Wittinghofer A., Oecking C. Structural view of a fungal toxin acting on a 14-3-3 regulatory complex. EMBO J. 2003, 22:987-994. 10.1093/emboj/cdg104.
89. Xu H.E., Stanley T.B., Montana V.G., Lambert M.H., Shearer B.G., Cobb J.E., McKee D.D., Galardi C.M., Plunket K.D., Nolte R.T., Parks D.J., Moore J.T., Kliewer S.a., Willson T.M., Stimmel J.B. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 2002, 415:813-817. 10.1038/415813a.
90. Zeeh J.C., Zeghouf M., Grauffel C., Guibert B., Martin E., Dejaegere A., Cherfils J. Dual specificity of the interfacial inhibitor brefeldin A for arf proteins and Sec7 domains. J. Biol. Chem. 2006, 281:11805-11814. 10.1074/jbc.M600149200.
91. 2+-sensing and SK channel activation. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:4828-4833. 10.1073/pnas.1220253110.
92. Zhang Q.C., Petrey D., Deng L., Qiang L., Shi Y., Thu C.A., Bisikirska B., Lefebvre C., Accili D., Hunter T., Maniatis T., Califano A., Honig B. Structure-based prediction of protein-protein interactions on a genome-wide scale. Nature 2012, 490:556-560. 10.1038/nature11503.
93. Zhang Y., Ng H.H., Erdjument-Bromage H., Tempst P., Bird A., Reinberg D. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes. Dev. 1999, 13:1924-1935. 10.1101/gad.13.15.1924.